JFG
ACOR

Jefferies Financial Group’s Acorda Therapeutics ACOR Stock Holding History

Jefferies Financial Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-112
Closed -$287K – 130
2017
Q4 		$287K Hold
112
– – 0.02% 105
2017
Q3 		$317K Buy
+112
New +$295K 0.03% 67

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Jefferies Financial Group's ACOR Position: Q1 2018 in Review

Jefferies Financial Group sold out of Acorda Therapeutics (ACOR) in Q1 2018, closing a stake of 112 shares — an estimated $287K sold.

Jefferies Financial Group first reported a position in ACOR in Q3 2017 and held it in 2 quarters. The position peaked at $317K in Q3 2017. 162 funds tracked by Wall St. Rank hold ACOR as of Q1 2018.

  • Jefferies Financial Group reported no remaining Acorda Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Jefferies Financial Group sold 112 Acorda Therapeutics shares in Q1 2018, an estimated $287K.
  • Jefferies Financial Group first reported a position in Acorda Therapeutics in Q3 2017 and held it in 2 quarters.
  • Jefferies Financial Group's Acorda Therapeutics position peaked at $317K in Q3 2017.
  • 162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2018.

Based on Jefferies Financial Group's 13F filing for Q1 2018, filed 15 May 2018.